Get the Stockscreener App
7.50
10.78%
0.73
Kala Bio Inc stock is traded at $7.50, with a volume of 136.66K.
It is up +10.78% in the last 24 hours and up +54.96% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$6.77
Open:
$6.58
24h Volume:
136.66K
Relative Volume:
1.19
Market Cap:
$48.39M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.6014
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
-7.29%
1M Performance:
+54.96%
6M Performance:
-18.48%
1Y Performance:
+19.43%
1-Day Range:
$6.50
$7.63
1-Week Range:
$6.46
$8.49
52-Week Range:
$2.92
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
7.50 | 43.68M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
Trend analysis for KALA BIO Inc. this weekFree Pattern Breakout Entry Stock Forecast - Newser
Is KALA BIO Inc. a Top Dividend Stock to Watch in 2025Free Trend Following Strategy With Stop Loss - Newser
Using portfolio simulators with KALA BIO Inc. includedFree Triple Digit Growth Focused Trade Plan - Newser
What makes KALA BIO Inc. stock price move sharplySwing Trade Outlook For Every Investor - jammulinksnews.com
How volatile is KALA BIO Inc. stock compared to the marketPre Market Forecasts Backed By Experts - jammulinksnews.com
How does KALA BIO Inc. compare to its industry peersPre Market Entry Points To Watch Now - jammulinksnews.com
Can you recover from losses in KALA BIO Inc.Entry Opportunity Screener with Confirmation - Newser
Why KALA BIO Inc. stock attracts strong analyst attentionFree Low Drawdown Real Time Trading Tips - Newser
KALA BIO Inc. Company’s Quarterly Earnings Growth: What the Numbers SayDaily Volume Spike Trading Signals Detected - metal.it
Can KALA BIO Inc. recover in the next quarterSafe Entry Zone Based on Chart Analysis - Newser
Is KALA BIO Inc. Stock a Smart Buy in 2025 Investment Analysis InsideNeural Model for Stock Price Movement - Newser
Combining price and volume data for KALA BIO Inc.High Return Strategy with Low Risk - Newser
How KALA BIO Inc. stock performs during market volatilityAI-Powered Stock Trend Movement Analysis - Newser
Is it the right time to buy KALA BIO Inc. stockValue Investing Entry Points With Proven Results - jammulinksnews.com
Should I hold or sell KALA BIO Inc. stock in 2025Stock Market Opportunities For Beginners - jammulinksnews.com
KALA BIO Inc. Breakout Confirmed by Volume MetricsStock Market Watch With Alerts Shows Unusual Activity - metal.it
Is KALA BIO Inc. stock overvalued or undervaluedFree Wealth Planning Blueprint - jammulinksnews.com
Zacks.com featured highlights include KALA, Graham, Arq and Hawkins - The Globe and Mail
What is KALA BIO Inc. company’s growth strategyHigh-octane gains - jammulinksnews.com
Is KALA BIO Inc. a growth stock or a value stockRetirement Planning Watchlist For Every Investor - jammulinksnews.com
KALA BIO (NASDAQ:KALA) Upgraded by Wall Street Zen to Hold Rating - Defense World
What catalysts could drive KALA BIO Inc. stock higher in 2025Achieve fast wealth growth with smart picks - jammulinksnews.com
What is the risk reward ratio of investing in KALA BIO Inc. stockFree AI-Backed Trading Signals - jammulinksnews.com
What institutional investors are buying KALA BIO Inc. stockDouble-digit growth - jammulinksnews.com
Published on: 2025-07-28 07:01:42 - jammulinksnews.com
Published on: 2025-07-28 00:55:50 - jammulinksnews.com
Moving Average Trends for KALA BIO Inc. Stock: What They Indicate200 Percent Watchlist - metal.it
What are KALA BIO Inc. company’s key revenue driversBuild a diversified portfolio for steady profits - jammulinksnews.com
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jun 24 '25 |
Sale |
4.01 |
3,631 |
14,560 |
62,100 |
| Bazemore Todd | SEE REMARKS |
Jun 24 '25 |
Sale |
4.01 |
4,058 |
16,273 |
83,699 |
| Brazzell Romulus K | SEE REMARKS |
Jun 24 '25 |
Sale |
4.01 |
5,251 |
21,057 |
82,698 |
| Iwicki Mark T | Director |
Jun 24 '25 |
Sale |
4.01 |
13,227 |
53,040 |
258,433 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):